Revolutionary clinical trial fast tracks trials for patients with brain tumor
the ONA take:
A new type of early phase clinical trial was recently introduced by the FDA, and is now being used to fast track potential drugs for the treatment of brain cancer.
Called Phase 0 trials, these early-phase clinical trials can shorten the evaluation of a drug from an average of 5 years to only 6 months at a much lower cost. Phase 0 trials occur outside the three lengthy phases of a standard clinical trial used to evaluate drug safety, effectiveness, side effects, and dosage.
In each single-patient trial, brain tumor experts at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center administer a drug already proven effective in other types of cancer to a participant with brain cancer. Barrow neurosurgeons remove the brain tumor within hours, and within weeks, determine whether the drug penetrated the blood-brain barrier to reach the tumor.
If the drug reached the tumor and is effective, it moves into a phase 2 clinical trial for patients. If it does not, the patient has the option to enter another study.
Barrow is conducting its phase 0 trials in partnership with The Ben & Catherine Ivy Foundation, the Translational Genomics Research Institute (TGen) and the Barbara Ann Karmanos Cancer Institute.

A new type of early phase clinical trial was recently introduced by the FDA, and is now being used to fast track potential drugs for the treatment of brain cancer.
Sign Up for Free e-newsletters
ONA Articles
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- Breast Cancer Treatment-Related Financial Burden Greater for Black vs White Women
- Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Olanzapine Use to Prevent Chemotherapy-Induced Nausea and Vomiting
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Intervention Improves Body Image-Related Distress in Survivors of Breast Cancer
- Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT
- Cancer Survivors May be More Prone to Polypharmacy
- Too Much Information: When Prognosis Breaks Down Patient Communications
- Breast Cancer Treatment-Related Financial Burden Greater for Black vs White Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |